Abstract
A novel CYP7A1 polymorphism is associated with the low-density lipoprotein cholesterol response to atorvastatin
Highlights
Statins are most widely prescribed to lowering circulating concentrations of LDL cholesterol for the prevention of CVD [1]
Several meta-analyses from randomized clinical trials have manifested that a statin-mediated reduction of 1mmol/l in LDL cholesterol yield a proportional reduction of approximately 20% in major vascular events [2,3]
Several studies have reported that CYP7A1 polymorphisms influence the LDL cholesterol-lowering response to atorvastatin [1215], such as the CYP7A1 A-204C*A in Caucasians and rs8192870*T in Chineses have a greater reduction in LDL cholesterol level response to atorvastatin as compared with variant allele-carrying genotype
Summary
Statins are most widely prescribed to lowering circulating concentrations of LDL cholesterol for the prevention of CVD [1]. The greater reductions in LDL cholesterol level, the larger reductions in vascular disease risk. The risk tends to increase with the increasing dosage of statins Such as myalgia, the reported incidence is 3-5% in clinical trials [5] and up to 10% among the patients of high-dose statins [6]. Information have urged us to research optimal atorvastatin treatment options, which aims at maximizing reduction of LDL cholesterol at the risk of minimal adverse effects. We preliminarily tempt to investigate the association between a novel CYP7A1 polymorphism rs8192875 and reductions of lipid levels response to atorvastatin in Chinese patients with coronary artery disease
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
